Choice of outcome measure
To minimize participant burden, outcomes need to be carefully selected. The Core Outcome Set Initiative (COUSIN), 7 which identifies the minimal set of core outcomes relevant to patients, carers and health decision-makers, is an excellent starting point. Following these guidelines ensures that a common set of outcomes are available across trials, facilitating meta-analysis. 7 Core outcome sets are being developed for a range of dermatological diseases. 8 There is no core outcome set for pyoderma gangrenosum, but the patients were involved in the choice of outcome measure to ensure relevance to the target population and avoid unnecessary burden. Moreover, the authors recognized that a lengthy follow-up leads to an increasing proportion of missing values and therefore chose a primary end point at 6 weeks of follow-up (velocity of healing), which was a good surrogate for subsequent healing.
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Strategies to minimize dropout Practical steps to reduce the burden on participants are likely to pay dividends. These include using data that do not require a clinic visit (e.g. routinely collected healthcare data), reducing the number of visits and allowing a relatively large time window for each assessment. 6 In the STOP GAP trial the time window was relatively large (16 weeks).
Imaginative strategies for maintaining follow-up
A skilled trial management team is at the heart of this. Maintaining follow-up is easier if patients give consent for followup separate to consent to treatment, so they can be followed up after any treatment withdrawal. A strategy of enhanced contact attempts (e.g. telephone) for a selection of nonresponders may also help. Participants in the STOP GAP trial were called by telephone when clinical visits were missed. With any trial there is a tension between internal and external validity, and this applies to missing data, too. We may target recruitment at patients who a priori we believe are more likely to remain in the study; by doing so we enhance our internal validity, possibly at the expense of external validity.
Analysis of incomplete data
The consequence of missing data is a loss of information to test our hypothesis (which may not be a simple factor of the proportion of observations missing). In our analysis, we can buy some of this information back with assumptions about the distribution of the missing values.
We assume that the data are not missing completely randomly. Beyond this, a natural starting point is to consider strata of patients who are in the same treatment group, and have similar baseline and early follow-up data. If we assume that such patients have the same distribution of their final end point regardless of whether we were able to observe it then we are essentially assuming the data are missing at random.
10
When some patients are missing later follow-up data, we can exploit this assumption to reduce the bias and increase the precision of the estimated treatment effect. 11 We can either do this using an appropriate longitudinal model for all the observed data, or equivalently we can use a technique called multiple imputation, 10 which is now implemented in a range of software packages. In analysing the STOP GAP trial, the authors rightly first explored whether the probability of missing outcome data depended on certain baseline variables, and whether these baseline variables predicted the missing values, finding they did both. Thus, data are not missing completely at random, so restricting the analysis to the subset of patients with no missing data (i.e. the completers) will generally result in bias and loss of information. Anticipating this, the authors' base-case analysis assumed values were missing at random, and used multiple imputation.
Multiple imputation generates a number of 'completed' datasets in which missing values are imputed under the 'missing-at-random' assumption. Roughly speaking, in each imputed dataset, each patient's missing final follow-up data are replaced by a draw from a pool of patients from the same treatment group who have closely matching baseline and early follow-up data. Since we can never know the missing values, only the 'pool' (i.e. statistical distribution) they belong to, a single imputed dataset is not sufficient. Instead, we create multiple imputed datasets, and in each one, each patient's missing values are replaced by a draw from their appropriate 'pool'. Then, we estimate the treatment effect from each imputed dataset, before combining the results using a set of simple rules (Rubin's rules) to arrive at the final treatment estimate, P-value and confidence interval. 12 The 'multiple' aspect of this process is key: in general, single imputation methods, such as last observation carried forward, generally lead to biased estimates and discard the uncertainty of imputation, leading to underestimated standard errors and misleading P-values.
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Sensitivity analysis of incomplete data
Sensitivity analysis explores the robustness of our scientific conclusions by doing different, contextually plausible, analysis assumptions. In the context of missing data, we explore the robustness of our conclusions to departures from the missingat-random assumption.
Recalling the discussion of Missing at random above, it follows that departures from this assumption occur if a patient with missing outcome data has outcome values that are systematically worse or better than what we would predict from a pool of patients from the same treatment group with broadly similar baseline and early follow-up data. In statistical terminology, departures from missing at random are called missing not at random.
The authors of the STOP GAP trial compared the results of their base-case multiple imputation based analysis with a complete case sensitivity analysis. The results of both analyses are compatible, although the multiple imputation analysis is more precise (i.e. narrower confidence intervals). Both the multiple imputation and complete case analyses adjust for the same covariates that are predictive of the potentially missing outcomes. The similarity of the resulting point estimates suggests that, given these covariates, the inclusion of outcome data during follow-up has relatively little effect on the predicted final outcomes. This reason for this is that the STOP GAP base-case and sensitivity analyses both rest on a broadly similar missing-at-random assumption.
To explore departures from missing at random, we need the imputed values to lie outside the missing-at-random 'pools'. It would have been interesting if the authors had explored 'missing not at random' scenarios. This can be achieved by changing the imputed values to represent the departure from missing at random. Once this is done, we proceed as before -analysing each imputed dataset and combining the results using Rubin's rules. The changes need to be contextually appropriate.
Last but not least: reporting of incomplete data
To improve statistical reporting, the BJD recommends that all authors follow the SAMPL guidelines. 15 These state that all supplementary analyses, such as imputation of missing data, should be described in the methods. Study-specific reporting guidelines also provide guidance for reporting of incomplete data. The STROBE statement for observational studies explicitly states that authors should address how missing data were handled in the analysis and that the number of participants with missing data for each variable of interest should be indicated. 15 The CONSORT guidelines state that the number of missing data should be reported by treatment arm. 15 To this we would add the following: the assumptions about missing data the analyses rest on should be accessibly reported, in particular the assumption about missing data that was specified in the protocol for the primary analysis. Further, when different assumptions lead to different scientific conclusions, the authors need to clearly communicate which assumptions are most contextually plausible.
The authors of the STOP GAP trial broadly complied with this, although, as we noted above, the extent that their sensitivity analysis explores departures from the missing-at-random assumption could be more fully discussed.
Conclusion: design holds the key!
Prevention is better than cure, and to minimize the loss of information due to missing data, it is important to consider the issues carefully in the design stage. Mechanisms of missing data can frequently be anticipated before the start of the study. Variables, which may be predictable for both the chance of data being missed and the missing value, should be included in the planned set of measurements. A practical solution is then to prespecify their use as part of a multiple imputation analysis assuming data are missing at random. Such an analysis will often be the primary analysis. Relatively simple multiple imputation-based sensitivity analysis can also usefully be prespecified. 16, 17 
